Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Degarelix - Ferring Pharmaceuticals

Next Previous
X
Search
Drug Profile

Degarelix - Ferring Pharmaceuticals

Alternative Names: ASP-3550; Degarelix acetate; FE-200486; Firmagon; Gonax; Uglypeptide-1

Latest Information Update: 26 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ferring Pharmaceuticals
  • Developer Astellas Pharma; Ferring Pharmaceuticals
  • Class Antineoplastics; Oligopeptides
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 26 Nov 2024 No development reported - Phase-III for Prostate cancer (Late-stage disease) in Slovakia, France, South Africa, Greece, Poland, Germany, Russia, Finland, United Kingdom, Czech Republic (SC)
  • 22 Jun 2022 Ferring Pharmaceuticals completes a phase II trial for Prostate Cancer (Late-stage disease, Combination therapy) in Sweden (SC, Injection, Powder, Solution) (EudraCT2016-004120-39)
  • 31 May 2022 Ferring Pharmaceuticals terminates the phase III PRONOUNCE trials in Prostate cancer (Late-stage disease) in Canada, Finland, France, Germany, Greece, Poland, Russia, Slovakia, South Africa, UK, USA and Czech republic (SC), due to recruitment rate; a lower-than-expected observed cardiovascular event rate. The Sponsor's decision to halt the trial was not influenced by issues imposed by the COVID-19 pandemic or based on any safety concerns or knowledge of the result (NCT02663908)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top